ClinicalTrials.gg
CompletedNCT04233801Updated Dec 15, 2023Results posted

A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin

A Phase 3 interventional study of Empagliflozin and Placebo in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 24 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-15.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
219
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Enrollment
34th of 130
219 · median 79
Started
2020
with 12 others
Phase 3
28 of 130
1 open now
Registered
76th of 130
by date
Lead sponsor
37 of 130
Boehringer Ingelheim

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 34th largest by enrollment, is one of 13 that started in 2020, is one of 28 in phase 3, and was the 76th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a study in Chinese adults with type 2 diabetes. The study is open to people who take insulin but still have too high blood sugar levels. Participants may additionally be taking up to 2 other medicines for their diabetes. The purpose of this study is to find out whether empagliflozin taken together with insulin helps people with type 2 diabetes to better control their blood sugar.

The participants are in the study for about 7 months. During this time, they visit the study site about 8 times, 1 additional visit may be either a visit to the study site or a phone call. At the start of the study, participants are put into 3 groups by chance. Participants get either 10 mg empagliflozin tablets, or 25 mg empagliflozin tablets, or placebo tablets once a day. Placebo tablets look like empagliflozin tablets but do not contain any medicine.

The doctors regularly take blood samples from the participants. The changes in blood sugar levels are compared between the groups. The doctors also check the general health of the participants.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years and ≤75 years old at Visit 1;
  • Chinese patient with diagnosis of Type 2 diabetes prior to Visit 1;
  • A stable treatment with premixed Insulin (≥ 20IU/day) or basal insulin (≥ 16 IU/day) for at least 12 weeks prior to enrolment with or without up to two OADs

    • With maximum insulin dose of ≤ 1 unit/kg/day. Acceptable basal insulins should have duration of action up to 24 h such as insulin Degludec, insulin glargin, insulin detemir or NPH (neutral protamine hagedorn) insulin; Acceptable pre-mixed insulins could be once or twice daily posology only. The total insulin dose should not be changed by more than 20% of the baseline value within the 12 weeks prior to randomisation (Visit 3). Both human insulin \& insulin analogue are acceptable;
    • If the patient is taking OADs, regimen has to be unchanged for at least 12 weeks prior to randomization (Visit 3);
    • If the patient is taking metformin, stable dose (at least 1500 mg daily or maximum tolerated dose) must be maintained for at least 12 weeks without dose adjustments prior to randomization (Visit 3);
  • ≥7.5% and ≤11.0% at Visit 1;
  • Fasting C-peptide: >0.5 ng/mL (>166pmol/L) at Visit 1;
  • 18.5 kg/m2 ≤ ≤ 45 kg/m2 at Visit 1;
  • Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial;
  • Male or female patients. Women of (WOCBP) must be ready and able to use highly effective methods of per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of Type 1 diabetes;
  • Patients receiving MDI insulin or insulin pump treatment;
  • \<45ml/min/1.73m2 calculated based on MDRD formula;
  • Uncontrolled hyperglycemia [glucose level >13. 9 mmol/l after an overnight fast during placebo run-in];
  • Severe hypoglycemia episode (event requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions) within 6 months prior to Visit 1;
  • History of diabetic ketoacidosis or hyperosmolar non-ketotic coma. Myocardial infarction, stroke or within 3 months prior to Visit 1;
  • Bariatric surgery;
  • Further criteria apply
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
219 participants (actual)

Study arms

  • Experimental
    Empagliflozin 10 mg

    1 table of 10 milligrams (mg) of Empagliflozin was administered orally once daily for a treatment period of 24 weeks. Before the first dose of randomised drug, all participants went through a 2-week open label placebo run-in period, taking Placebo tablets orally once daily.

    Drug: Empagliflozin

  • Experimental
    Empagliflozin 25 mg

    1 table of 25 milligrams (mg) of Empagliflozin was administered orally once daily for a treatment period of 24 weeks. Before the first dose of randomised drug, all participants went through a 2-week open label placebo run-in period, taking Placebo tablets orally once daily.

    Drug: Empagliflozin

  • Placebo comparator
    Placebo

    Matching placebo was administered orally once daily for a treatment period of 24 weeks. Before the first dose of randomised drug, all participants went through a 2-week open label placebo run-in period, taking Placebo tablets orally once daily.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 24

    A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including treatment, background therapy, and visit as fixed classification effects, baseline HbA1c and baseline estimated glomerular filtration rate (eGFR) as the linear covariates, treatment by visit interaction, and baseline HbA1c by visit interaction.

    Time frame: At baseline (Week 0) and at Week 24

Secondary outcomes

  1. Percentage of Participants With HbA1c<7.0% at Week 24

    Percentage of participants with glycosylated haemoglobin A1c (HbA1c) \<7.0% at Week 24 is reported.

    Time frame: At Week 24

  2. Change in Body Weight From Baseline to Week 24

    Change in body weight from baseline to Week 24 is reported. A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including baseline body weight, and its interaction with visit.

    Time frame: At baseline (Week 0) and at Week 24

  3. Change From Baseline in Systolic Blood Pressure (SBP) at Week 24

    A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including baseline SBP and its interaction with visit.

    Time frame: At baseline (Week 0) and at Week 24

  4. Change From Baseline in Diastolic Blood Pressure (DBP) at Week 24

    A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including baseline DBP and its interaction with visit.

    Time frame: At baseline (Week 0) and at Week 24

  5. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

    A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including baseline FPG and its interaction with visit.

    Time frame: At baseline (Week 0) and at Week 24

  6. Change From Baseline in 2-hour Post-prandial Glucose (PPG) at Week 24

    The Analysis of covariance (ANCOVA) model included treatment and background therapy as classification effects, baseline PPG and baseline Estimated glomerular filtration rate (eGFR) as the linear covariates.

    Time frame: At baseline (Week 0) and at Week 24

  7. Number of Participants With Confirmed Hypoglycaemic Events

    Confirmed hypoglycemic events refer to the hypoglycaemic events with a plasma glucose value of ≤70 milligrams per deciliter (mg/dL) or where assistance was required.

    Time frame: From first administration of the initial randomised study medication to last intake of study medication + 7 days (inclusive), up to 176 days.

  8. Number of Participants With Adjudicated Diabetic Ketoacidosis (DKA) Events

    The risk of DKA had to be considered in the event of non-specific symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty in breathing, confusion, unusual fatigue or sleepiness. In case of a suspected DKA, the investigator was to ensure that appropriate tests were performed at the earliest opportunity according to 2017 China Type 2 diabetes mellitus (T2DM) guidelines. An independent external Clinical event committee (CEC) was established to adjudicate centrally and in a blinded fashion events suspected of DKA and certain hepatic events. DKA was investigated using both broad and narrow Boehringer Ingelheim customised MedDRA query (BIcMQs).

    Time frame: From first administration of the initial randomised study medication to last intake of study medication + 7 days (inclusive), up to 176 days.

07

Results

Posted Dec 15, 2023

Participant flow

This study was to determine the efficacy and safety of Empagliflozin added to insulin-treated type 2 diabetes patients.

Participant flow — Overall Study
MilestonePlaceboEmpagliflozin 10 mgEmpagliflozin 25 mg
Started737373
Completed737169
Not completed024
Withdrew: Other than listed001
Withdrew: Withdrawal by subject023

Outcome measures

PrimaryChange From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 24

A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including treatment, background therapy, and visit as fixed classification effects, baseline HbA1c and baseline estimated glomerular filtration rate (eGFR) as the linear covariates, treatment by visit interaction, and baseline HbA1c by visit interaction.

Time frame:
At baseline (Week 0) and at Week 24
Reported as:
Least squares mean · Percentage of glycosylated hemoglobin
Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 24
Percentage of glycosylated hemoglobinPlaceboEmpagliflozin 10 mgEmpagliflozin 25 mg
Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 24-0.13 ± 0.10-1.12 ± 0.10-1.12 ± 0.10
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Mixed model repeated measures · p = < 0.0001 · Adjusted mean: -0.99 · 95% CI -1.28 to -0.71
  • Placebo vs Empagliflozin 25 mg · Mixed model repeated measures · p = < 0.0001 · Adjusted mean: -0.98 · 95% CI -1.26 to -0.70
SecondaryPercentage of Participants With HbA1c<7.0% at Week 24

Percentage of participants with glycosylated haemoglobin A1c (HbA1c) \<7.0% at Week 24 is reported.

Time frame:
At Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With HbA1c<7.0% at Week 24
Percentage of participantsPlaceboEmpagliflozin 10 mgEmpagliflozin 25 mg
Percentage of Participants With HbA1c<7.0% at Week 248.216.730.1
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Regression, Logistic · p = 0.1375 · Odds ratio (or): 2.29 · 95% CI 0.77 to 6.83
  • Placebo vs Empagliflozin 25 mg · Regression, Logistic · p = 0.0008 · Odds ratio (or): 6.01 · 95% CI 2.11 to 17.10
SecondaryChange in Body Weight From Baseline to Week 24

Change in body weight from baseline to Week 24 is reported. A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including baseline body weight, and its interaction with visit.

Time frame:
At baseline (Week 0) and at Week 24
Reported as:
Least squares mean · Kilogram
Change in Body Weight From Baseline to Week 24
KilogramPlaceboEmpagliflozin 10 mgEmpagliflozin 25 mg
Change in Body Weight From Baseline to Week 240.01 ± 0.23-1.99 ± 0.24-1.31 ± 0.24
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Mixed model repeated measures · p = < 0.0001 · Adjusted mean: -2.00 · 95% CI -2.66 to -1.34
  • Placebo vs Empagliflozin 25 mg · Mixed model repeated measures · p = < 0.0001 · Adjusted mean: -1.32 · 95% CI -1.96 to -0.67
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) at Week 24

A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including baseline SBP and its interaction with visit.

Time frame:
At baseline (Week 0) and at Week 24
Reported as:
Least squares mean · Millimetre of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) at Week 24
Millimetre of mercury (mmHg)PlaceboEmpagliflozin 10 mgEmpagliflozin 25 mg
Change From Baseline in Systolic Blood Pressure (SBP) at Week 24-1.95 ± 1.38-5.56 ± 1.49-2.96 ± 1.46
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Mixed model repeated measures · p = 0.0774 · Adjusted mean: -3.60 · 95% CI -7.61 to 0.40
  • Placebo vs Empagliflozin 25 mg · Mixed model repeated measures · p = 0.6160 · Adjusted mean: -1.01 · 95% CI -4.98 to 2.96
SecondaryChange From Baseline in Diastolic Blood Pressure (DBP) at Week 24

A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including baseline DBP and its interaction with visit.

Time frame:
At baseline (Week 0) and at Week 24
Reported as:
Least squares mean · Millimetre of mercury (mmHg)
Change From Baseline in Diastolic Blood Pressure (DBP) at Week 24
Millimetre of mercury (mmHg)PlaceboEmpagliflozin 10 mgEmpagliflozin 25 mg
Change From Baseline in Diastolic Blood Pressure (DBP) at Week 24-1.59 ± 0.78-3.37 ± 0.84-0.94 ± 0.83
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Mixed model repeated measures · p = 0.1222 · Adjusted mean: -1.78 · 95% CI -4.05 to 0.48
  • Placebo vs Empagliflozin 25 mg · Mixed model repeated measures · p = 0.5687 · Adjusted mean: 0.65 · 95% CI -1.59 to 2.89
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 24

A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including baseline FPG and its interaction with visit.

Time frame:
At baseline (Week 0) and at Week 24
Reported as:
Least squares mean · Milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
Milligrams per deciliter (mg/dL)PlaceboEmpagliflozin 10 mgEmpagliflozin 25 mg
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24-5.56 ± 3.67-25.61 ± 3.97-29.69 ± 3.90
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Mixed model repeated measures · p = 0.0003 · Adjusted mean: -20.05 · 95% CI -30.73 to -9.38
  • Placebo vs Empagliflozin 25 mg · Mixed model repeated measures · p = <0.0001 · Adjusted mean: -24.13 · 95% CI -34.72 to -13.54
SecondaryChange From Baseline in 2-hour Post-prandial Glucose (PPG) at Week 24

The Analysis of covariance (ANCOVA) model included treatment and background therapy as classification effects, baseline PPG and baseline Estimated glomerular filtration rate (eGFR) as the linear covariates.

Time frame:
At baseline (Week 0) and at Week 24
Reported as:
Least squares mean · Milligrams per deciliter (mg/dL)
Change From Baseline in 2-hour Post-prandial Glucose (PPG) at Week 24
Milligrams per deciliter (mg/dL)PlaceboEmpagliflozin 10 mgEmpagliflozin 25 mg
Change From Baseline in 2-hour Post-prandial Glucose (PPG) at Week 243.27 ± 7.53-53.05 ± 8.14-57.44 ± 7.89
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · ANCOVA · p = <0.0001 · Adjusted mean: -56.32 · 95% CI -78.22 to -34.41
  • Placebo vs Empagliflozin 25 mg · ANCOVA · p = <0.0001 · Adjusted mean: -60.71 · 95% CI -82.31 to -39.11
SecondaryNumber of Participants With Confirmed Hypoglycaemic Events

Confirmed hypoglycemic events refer to the hypoglycaemic events with a plasma glucose value of ≤70 milligrams per deciliter (mg/dL) or where assistance was required.

Time frame:
From first administration of the initial randomised study medication to last intake of study medication + 7 days (inclusive), up to 176 days.
Reported as:
Count of participants · Participants
Number of Participants With Confirmed Hypoglycaemic Events
ParticipantsPlaceboEmpagliflozin 10 mgEmpagliflozin 25 mg
Number of Participants With Confirmed Hypoglycaemic Events8137
Statistical analysis
  • Placebo vs Empagliflozin 10 mg · Regression, Logistic · p = 0.2422 · Odds ratio (or): 1.76 · 95% CI 0.68 to 4.55Odds ratio used Placebo as the reference group.
  • Placebo vs Empagliflozin 25 mg · Regression, Logistic · p = 0.7661 · Odds ratio (or): 0.85 · 95% CI 0.29 to 2.50Odds ratio used Placebo as the reference group.
SecondaryNumber of Participants With Adjudicated Diabetic Ketoacidosis (DKA) Events

The risk of DKA had to be considered in the event of non-specific symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty in breathing, confusion, unusual fatigue or sleepiness. In case of a suspected DKA, the investigator was to ensure that appropriate tests were performed at the earliest opportunity according to 2017 China Type 2 diabetes mellitus (T2DM) guidelines. An independent external Clinical event committee (CEC) was established to adjudicate centrally and in a blinded fashion events suspected of DKA and certain hepatic events. DKA was investigated using both broad and narrow Boehringer Ingelheim customised MedDRA query (BIcMQs).

Time frame:
From first administration of the initial randomised study medication to last intake of study medication + 7 days (inclusive), up to 176 days.
Reported as:
Count of participants · Participants
Number of Participants With Adjudicated Diabetic Ketoacidosis (DKA) Events
ParticipantsPlaceboEmpagliflozin 10 mgEmpagliflozin 25 mg
Number of Participants With Adjudicated Diabetic Ketoacidosis (DKA) Events000

Adverse events

Collected over For Run-in period group: from first dose of open label placebo till end of run-in period, up to 2 weeks. For the other groups: From first administration of the initial randomised study medication to last intake of study medication + 7 days (inclusive), up to 176 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/73 (0%)6/73 (8.2%)39/73 (53.4%)
Empagliflozin 10 mg0/73 (0%)10/73 (13.7%)27/73 (37%)
Empagliflozin 25 mg0/73 (0%)7/73 (9.6%)27/73 (37%)
Run-in Period0/219 (0%)2/219 (0.9%)46/219 (21%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventPlaceboEmpagliflozin 10 mgEmpagliflozin 25 mgRun-in Period
Angina unstableCardiac disorders0/730/731/730/219
ArrhythmiaCardiac disorders0/731/730/730/219
Arteriosclerosis coronary arteryCardiac disorders0/731/731/730/219
Deafness neurosensoryEar and labyrinth disorders1/730/730/730/219
HyperparathyroidismEndocrine disorders0/731/730/730/219
Thyroid massEndocrine disorders0/731/730/730/219
CataractEye disorders0/730/731/730/219
Duodenal ulcer haemorrhageGastrointestinal disorders0/731/730/730/219
Cholecystitis chronicHepatobiliary disorders0/731/730/730/219
CholelithiasisHepatobiliary disorders0/731/730/730/219
Most frequent other events
Most frequent other events
EventPlaceboEmpagliflozin 10 mgEmpagliflozin 25 mgRun-in Period
HypoglycaemiaMetabolism and nutrition disorders11/7315/7311/739/219
Urinary tract infectionInfections and infestations10/736/736/7310/219
HyperglycaemiaMetabolism and nutrition disorders7/730/733/730/219
Diabetic nephropathyRenal and urinary disorders6/730/731/7311/219
Upper respiratory tract infectionInfections and infestations5/734/734/733/219
Electrocardiogram T wave abnormalInvestigations5/731/732/730/219
Protein urine presentInvestigations4/732/733/7315/219
HyperlipidaemiaMetabolism and nutrition disorders2/734/734/731/219

Baseline characteristics

Treated set (TS): The TS consisted of all patients who were randomised and treated with at least one dose of the study drug. The assignment of patients to treatment groups were based on the actual first study drug intake in the double-blind treatment period.

Age, Continuous
Age, Continuous(Years)PlaceboEmpagliflozin 10 mgEmpagliflozin 25 mgTotal
Mean60.1 ± 8.059.9 ± 7.760.7 ± 9.160.2 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEmpagliflozin 10 mgEmpagliflozin 25 mgTotal
Female373033100
Male364340119
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboEmpagliflozin 10 mgEmpagliflozin 25 mgTotal
American Indian or Alaska Native0000
Asian737373219
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Glycosylated haemoglobin A1c (HbA1c)
Glycosylated haemoglobin A1c (HbA1c)(Percentage of glycosylated hemoglobin)PlaceboEmpagliflozin 10 mgEmpagliflozin 25 mgTotal
Mean8.64 ± 0.818.64 ± 0.918.64 ± 0.888.64 ± 0.87
Time since diagnosis of diabetes
Time since diagnosis of diabetes(Years)PlaceboEmpagliflozin 10 mgEmpagliflozin 25 mgTotal
Mean14.14 ± 7.2614.74 ± 7.0115.05 ± 7.4514.64 ± 7.22
Background antidiabetic treatment
Background antidiabetic treatment(Participants)PlaceboEmpagliflozin 10 mgEmpagliflozin 25 mgTotal
Insulin + Oral antidiabetic drug (OAD)605959178
Insulin only13141441
Type of insulin
Type of insulin(Participants)PlaceboEmpagliflozin 10 mgEmpagliflozin 25 mgTotal
Basal323834104
Pre-mixed413539115
08

Study locations

24 sites
  • Peking University First Hospital
    Beijing, 100034, China
  • Peking University People's Hospital
    Beijing, 100044, China
  • Peking University Third Hospital
    Beijing, 100191, China
  • Beijing Pinggu Hospital
    Beijing, 101200, China
  • The Second Hospital of Jilin University
    Changchun, 130041, China
  • The third xiangya hospital of Central South University
    Changsha, 410013, China
  • The First Hospital, Chongqing Medical University
    Chongqing, 400042, China
  • Chongqing Three Gorges Central Hospital
    Chongqing, 404000, China
  • Third Affiliated Hospital of Guangzhou Medical University
    Guangzhou, 510150, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Hangzhou, 210011, China
  • The Affiliated Hospital of Hangzhou Normal University
    Hangzhou, 310015, China
  • Anhui Provincial Hospital
    Hefei, 230001, China
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, 471000, China
  • Jiangxi Provincial People's Hospital
    Nanchang, 330006, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, 330006, China
  • The Second Affiliated Hospital to Nanchang University
    Nanchang, 330006, China
  • The affiliated hospital of medicalcollege qingdao university
    Qingdao, 266005, China
  • Tongren hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, 200051, China
  • Centre Hospital of Putuo District, Shanghai
    Shanghai, 200062, China
  • Shanghai Fifth People's Hospital affiliated to Fudan University
    Shanghai, 200240, China
  • Shengjing Hospital of China Medical University
    Shenyang, 110072, China
  • Suzhou Municipal Hospital
    Suzhou, 215002, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, 215006, China
  • Tianjin Medical University Chu Hisen-I Memorial Hospital
    Tianjin, 300070, China
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Mar 2022, 22 months.

Results were first posted in Dec 2023, 1 year 9 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 22 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2020
First posted
Jan 18, 2020
StartActual
Apr 15, 2020
Primary completionActual
Mar 3, 2022
CompletionActual
Mar 10, 2022
Results first posted
Dec 15, 2023
Last update
Dec 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04233801
Responsible party
Sponsor
First posted
Jan 18, 2020
Start date
Apr 15, 2020
Primary completion
Mar 3, 2022
Completion
Mar 10, 2022
Results posted
Dec 15, 2023
Last update
Dec 15, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion